Patient Education Sheet Library
Search Results
Sirolimus
Sirolimus is used for graft-versus-host disease (GVHD) and certain types of soft tissue sarcoma.
Treatment Taken by MouthDownloads:
Download (English)Tacrolimus
Tacrolimus is used for graft-versus-host disease (GVHD).
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Cyclophosphamide, Bortezomib, and Dexamethasone
The combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD or VCD) is used for multiple myeloma…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Belantamab Mafodotin and Vd
The combination of belantamab mafodotin, bortezomib, and dexamethasone (BVd) is used for multiple myeloma (MM).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Zanubrutinib and Obinutuzumab
The combination of zanubrutinib and obinutuzumab is used for follicular lymphoma (FL).
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Relacorilant and Albumin-Bound Paclitaxel
The combination of relacorilant and albumin-bound paclitaxel is used for ovarian, fallopian tube, or primary…
Treatment Given by Injection Treatment Taken by MouthDownloads:
Rituximab, Methotrexate, and Temozolomide
The combination of rituximab, methotrexate, and temozolomide is used for primary central nervous system lymphoma…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Vemurafenib and Obinutuzumab
The combination of vemurafenib and obinutuzumab is used for hairy cell leukemia (HCL).
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Vemurafenib and Rituximab
The combination of vemurafenib and rituximab is used for hairy cell leukemia (HCL).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Acalabrutinib and Rituximab
The combination of acalabrutinib and rituximab is used for mantle cell lymphoma (MCL).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
